Bone Effects of Rosiglitazone in HIV-Infected Patients With Lipoatrophy

Carotid Intima Media Thickness, Inflammatory Markers, and Endothelial Activation Markers in HIV Patients with Lipoatrophy Increased at 48 Weeks Regardless of Use of Rosiglitazone or Placebo

(2010) Marisa Tungsiripat et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Exercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity

(2010) Kevin E. Yarasheski et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes

(2010) R. E. Aubert et al.   DIABETES OBESITY & METABOLISM

A Meta-Analysis of Six Placebo-Controlled Trials of Thiazolidinedione Therapy for HIV Lipoatrophy

(2010) Janet M. Raboud et al.   HIV CLINICAL TRIALS

Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards

(2010) S. Vasikaran et al.   OSTEOPOROSIS INTERNATIONAL

Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients

(2009) Claudine Duvivier et al.   AIDS

Osteoporosis in Inflammatory Bowel Disease

(2009) Tauseef Ali et al.   AMERICAN JOURNAL OF MEDICINE

Relationship between Inflammatory Markers, Endothelial Activation Markers, and Carotid Intima‐Media Thickness in HIV‐Infected Patients Receiving Antiretroviral Therapy

(2009) Allison C. Ross et al.   CLINICAL INFECTIOUS DISEASES

PPAR-γ agonist rosiglitazone prevents inflammatory periodontal bone loss by inhibiting osteoclastogenesis

(2009) Márcio Y. Hassumi et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Loss of Bone Mineral Density After Antiretroviral Therapy Initiation, Independent of Antiretroviral Regimen

(2009) Todd T Brown et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

The Risk of Fractures Associated with Thiazolidinediones: A Self-controlled Case-Series Study

(2009) Ian J. Douglas et al.   PLOS MEDICINE

Use of Thiazolidinediones and Fracture Risk

(2008) Christian Meier et al.   ARCHIVES OF INTERNAL MEDICINE

Endothelial Activation Markers Are Linked to HIV Status and Are Independent of Antiretroviral Therapy and Lipoatrophy

(2008) Allison C Ross et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Fracture Prevalence among Human Immunodeficiency Virus (HIV)-InfectedVersusNon-HIV-Infected Patients in a Large U.S. Healthcare System

(2008) Virginia A. Triant et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effect of Rosiglitazone on Peroxisome Proliferator‐Activated Receptor γ Gene Expression in Human Adipose Tissue Is Limited by Antiretroviral Drug–Induced Mitochondrial Dysfunction

(2008) Patrick W. G. Mallon et al.   JOURNAL OF INFECTIOUS DISEASES

Biomarkers of bone health and osteoporosis risk

(2008) Richard Eastell et al.   PROCEEDINGS OF THE NUTRITION SOCIETY

Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis

(2008) Meriem Koufany et al.   ARTHRITIS RESEARCH & THERAPY